| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;51:848.)
© 2008 American Heart Association, Inc.
Original Articles |
gorzata Brzozowska-Kiszka
gorzata Kloch-Bade
ek
ski
oFrom the I Department of Cardiology and Hypertension (P.J., K.K.-J., D.C., M.B.-K., K.S., M.L., M.K.-B., J.W., A.M.C.) and the II Department of Cardiology (D.D.), Collegium Medicum Jagiellonian University, Kraków, Poland.
Correspondence to Piotr Jankowski, I Department of Cardiology and Hypertension, Jagiellonian University Medical College, 17 Kopernik St, 31-501 Kraków, Poland. E-mail piotrjankowski{at}interia.pl
| Abstract |
|---|
|
|
|---|
Key Words: blood pressure central pulse pressure pulsatility cardiovascular risk atherosclerosis coronary artery disease
| Introduction |
|---|
|
|
|---|
Although the differences between central and peripheral BP values have been known for decades, the consequences of decision making based on peripheral rather than central BP have only recently been recognized.6–9 As central BP directly affects heart and coronary as well as carotid arteries and is directly related to the incidence of major cardiovascular complications, more and more attention is being given to the ascending aortic BP measurements.6,7 There are only a few studies assessing the relationship between central BP and cardiovascular risk. The relationship between pulsatility (as measured invasively in the ascending aorta) and the risk of cardiovascular events has not yet been evaluated. Therefore, the present study was designed for the assessment of the relationship between prognosis and the steady and pulsatile components of central BP.
| Methods |
|---|
|
|
|---|
The study group consisted of 1150 patients. Among them 299 (26.0%) were women and 851 (74.0%) were men. Study end points were ascertained for 1109 (96.4%) patients. Furthermore, only the cause and date of death was obtained for 3 participants whereas only date of death for one patient. Thirty seven (3.2%) patients were lost to follow-up.
We examined a possible bias in the formation of the analyzed population by comparing it with respect to age, gender, risk factors, heart failure, and values of BPs as well as mean value of ejection fraction (EF) with the data from a population consisting of 41 patients for which there was no whole follow-up information. These comparisons showed no statistically significant differences with respect to all of the above factors.
Baseline Data Collection
Fasting blood samples were taken before coronary angiography for the analysis of lipids as well as glycemia and creatinine levels. Diabetes was defined as a fasting blood glucose level of 7.0 mmol/L or more or the use of an antidiabetic drug. No differentiation was made between type 1 and type 2 diabetes during analysis because of the low number of patients with type 1 diabetes. Participants with total cholesterol levels
5.2 mmol/L or being prescribed a lipid-lowering drug were considered as having hypercholesterolemia. Hypertension was defined as a high brachial BP (SBP
140 mm Hg or DBP
90 mm Hg) or prescription of a BP-lowering drug for high BP. Glomerular filtration rate (GFR) was calculated using abbreviated MDRD study equation. Present smokers were defined as those who smoked any tobacco in the previous month. EF was determined using contrast ventriculography.
Brachial BP was measured twice using a mercury sphygmomanometer ("STANDBY" Model, W.A. BAUM Co Inc). Measurements were made under standardized conditions, between 8 and 11 AM. Patients were seated for measurements, had not eaten or smoked for at least 30 min, and had rested for 10 min. BP for individual participants was calculated as the average of the 2 readings.
Central BP measurements were obtained in the supine position. Aortic SBP and DBP were measured in the ascending aorta using a low-compliance fluid-filled system (the natural frequency of the system was 17 Hz and the damping coefficient 0.35). The transducer was localized on the level of aortic valve. It was calibrated with mercury manometer. MBP was obtained by direct integration of the BP curve. PP was calculated as the difference between SBP and DBP. Pulsatility was calculated as PP divided by MBP.3
Cardiac catheterization was performed according to a standard technique. Coronary angiograms were scored using 2 techniques:
Number of Diseased Arteries
The 3 major coronary vessels (left anterior descending artery, circumflex artery, and right coronary artery) and their branches were evaluated for the extent of coronary atherosclerosis. A diseased artery was defined as >50% stenosis in at least 1 of its segments. Significant left main artery stenosis was coded as 2-vessel disease.
Mean Stenosis
The maximum stenosis was measured in 15 segments (as defined by the American Heart Association10), and the mean stenosis was then calculated.
All physicians followed European Society of Cardiology guidelines when considering myocardial revascularization. All cardiovascular drugs taken within 24 hours before catheterization were analyzed. The following medication classes were considered in the analysis: antiplatelets, β-blockers, ACE-inhibitors, calcium antagonists, diuretics, nitrates, statins, fibrates, digoxin, oral hypoglycemics, and insulin.
Study End Points
Study end points were assessed over a 4.5-year follow-up period. A standardized questionnaire was sent to every participant. In case of no response the second questionnaire was sent. If the answer was still not obtained family or neighbors were contacted. Every effort was made to determine the patients status. If the answer was obtained and the patient reported no health problems no further contact was made. However, in case of any health problem patient was contacted personally. The diagnosis of MI, stroke, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), nonfatal cardiac arrest, and heart transplantation was made on the basis of medical documentation.
The primary end point was defined as cardiovascular death or nonfatal MI or nonfatal stroke or nonfatal cardiac arrest or PCI or CABG or heart transplantation. The secondary end point was defined as cardiovascular death or nonfatal MI or nonfatal stroke. Cardiovascular events which occurred within 24 hours after coronary angiography (stroke in 1 patient, ventricular fibrillation in 2 patients, and sustained ventricular tachycardia in 2 patients) were not included in the analysis as they were considered as procedure-related.
Statistical Analysis
Categorical variables are reported as percentages and continuous variables as means±SD. Normally distributed continuous variables were compared using Student t test. Mann-Whitney U test was used in case of variables without normal distribution. The Pearson
2 test was applied to all categorical variables. A 2-tailed probability value of less than 0.05 was considered to indicate statistical significance. Correlations between BP-related indices and coronary atherosclerosis measures were calculated using Spearman correlation. The standardized by age (in 5-year strata) and gender rates of primary end point according to quartiles of central and peripheral MBP, PP, and pulsatility were calculated.
Coxs proportional hazards models were used to determine the effects of BP-derived indices and the other variables on the occurrence of primary and secondary end points in both univariate and multivariate analyses. Commencing with all variables presented in Table 1 and prescribed medications stepwise regression analysis was performed using probability value >0.05. To compare the prognostic value of BP-related indices, each index was included separately into the model containing all independent predictors of the end point. The risk associated with BP-derived indices is reported according to the standard deviation increase in the value of each index. This allows easy comparison of the prognostic value of these indices. As the next step we constructed 2 models: model 1 consisted of age, gender, and a BP-related index, whereas model 2 consisted of the above variables plus ejection fraction, mean coronary artery stenosis, heart failure, heart rate, risk factors, cardiovascular history, GFR, and prescribed drugs. Afterward we performed additional multivariate analysis: central MBP was forced to the above described models together with central PP, then with central pulsatility, and finally central PP together with central pulsatility were analyzed. We repeated the above analyses using calculated (from SBP and DBP) central and peripheral MBP.
|
Subgroup analysis examined the relationship between BP-derived indices and the risk of primary end point according to variables which were significant predictors of the event-free survival in multivariate analysis of the whole study group. Additionally, subgroup analysis according to age, previous myocardial revascularization procedures, heart failure, and hypertension was performed. Only BP-derived indices which were independent predictors of the primary end point occurrence in the whole study group were included in this part of the analysis. Test for interaction in the Cox model was used to compare hazard ratios between the analyzed subgroups. We also calculated Receiver Operator Characteristics curves. All data were analyzed using STATISTICA 6.0 software (StatSoft, Inc).
| Results |
|---|
|
|
|---|
30.0 kg/m2) was found in 259 (23.4%) patients, whereas 557 (50.2%) participants were overweight (body mass index 25.0 to 30.0 kg/m2). Left ventricular EF
55% was observed in 739 (66.6%) patients, whereas 101 (9.1%) subjects had EF below 40%. The central BP values as well as pulsatility at baseline are shown in Table 2. The brachial BPs are presented in Table S1 (available in an online data supplement at http://hyper.ahajournals.org). The proportions of patients treated with cardiovascular drugs during 24-hours before catheterization are presented in Table S2. On the basis of coronary angiography, 1-vessel CAD was found in 271 (24.4%) patients, 2-vessel disease in 254 (22.9%), and 3-vessel disease in 349 (31.5%) participants, whereas 235 (21.2%) patients had no significant atherosclerotic lesion in the coronary tree. The mean stenosis of coronary artery segments was 19.3±13.1%. Of 874 patients with significant (>50%) lesions in coronary arteries, 323 (37.0%) were subsequently treated conservatively, 357 (40.8%) underwent PCI, and 194 (22.2%) underwent CABG.
|
Mean stenosis of coronary artery correlated better with BP-derived indices (data not shown) than the number of diseased arteries. Similarly, mean stenosis was correlated better with BPs as well as with pulsatility in patients with normal left ventricular EF (
55%). In patients with left ventricular EF <55% BPs did not correlate with any coronary atherosclerosis measures. On the other hand the correlation between mean stenosis and central pulsatility only just reached statistical significance. On the basis of these observations, the mean stenosis was used as a measure of coronary atherosclerosis in the subsequent multivariate analyses.
During a mean follow-up time of 52.7±19.2 months 90 deaths were recorded. The mean follow-up time for those who survived until the end of the follow-up was 55.0±17.2 months. During the follow-up there were 71 (6.4%) cardiovascular deaths, 91 (8.2%) nonfatal myocardial infarctions, 28 (2.5%) nonfatal strokes, and 1 (0.1%) nonfatal cardiac arrest. One patient (0.1%) underwent heart transplantation, 116 (10.5%) underwent PCI, and 26 (2.3%) CABG, whereas 10 participants (0.9%) underwent both PCI and CABG.
The primary end point occurred in 246 (22.2%) patients (198 men and 48 women). The standardized by age and gender event rates according to quartiles of central MBP, PP, and pulsatility are presented on (Figure 1). The risk of primary end point was not related to the quartiles of MBP. On the other hand it was significantly higher in the 4th quartile of central PP compared to 1st and 2nd. The risk was also significantly higher in 3rd and 4th quartiles of central pulsatility compared to 1st quartile. The event rates did not differ among quartiles of peripheral MBP, PP, or pulsatility. Independent predictors of the primary end point are shown in Table 3. According to the Wald statistics value the most powerful predictor of the primary end point was EF. When central pulsatility was added to the model consisting of all independent predictors (EF, mean coronary stenosis, previous MI, sex, GFR, diabetes) it occurred the most powerful predictor. When central PP was included instead of pulsatility it appeared to be more strongly related to the cardiovascular risk than any of non–BP-related variables. If other BP-related parameters were included into the model they were not independently related to the risk of the primary end point.
|
|
Table 4 shows hazard ratios of the primary end point according to MBP, PP, and pulsatility. MBP was not related to the risk of the primary end point. Central PP and central pulsatility were related to the cardiovascular risk both after age and gender adjustment as well as after adjustment for a number of other variables.
|
When central MBP and central PP were forced together into the above statistical models only central PP occurred significantly related to the cardiovascular risk (Table 5). Similarly, when central pulsatility was forced into the models together with MBP only the former variable occurred a predictor of the primary end point. When central PP and central pulsatility were analyzed together none of them reached the significance level. However, after adjustments for age and gender central pulsatility but not central PP was significantly related to the risk of primary end point. We repeated the above analyses using calculated central and peripheral MBP. The results did not differ significantly (Table S3). Subgroup analyses are presented on (Figures 2 and 3
). We found no significant heterogeneity among analyzed subgroups. We also calculated ROC curves. The area under the curve was 0.52 (95% CI 0.47 to 0.56) for central MBP, 0.57 (0.53 to 0.62) for central PP, and 0.58 (0.54 to 0.63) for central pulsatility.
|
|
|
Secondary end point consisted of cardiovascular death or nonfatal MI or nonfatal stroke occurred in 144 (13.0%) patients. The independent predictors of the end point are shown in Table S4. According to the Wald statistics value the most powerful predictor of the secondary end point was GFR. When central pulsatility was added to the model it occurred independently related to the end point. If other BP-related parameters were included into the model they were not independent predictors.
| Discussion |
|---|
|
|
|---|
Steady component of BP (represented by MBP) was not related to the cardiovascular risk in our study population. This finding agrees with some previous studies.20 In contrast, pulsatile components of BP parameters were significant predictors of cardiovascular risk. Our findings concur with the results of several small studies showing independent relationship between intra-aortic pulsatility and pulsatility index and the risk of restenosis in patients undergoing coronary angioplasty3,4 as well as with the results of Chirinos et al who showed a correlation between central PP and cardiovascular risk in men with angiographically confirmed CAD.21 Although these authors did not include the extent of the coronary atherosclerosis into the multivariable analysis21 we did include it and therefore we were able to show that the relationship between central pulse pressure and cardiovascular risk is independent of the coronary atherosclerosis extent in subjects with CAD. Moreover, to our best knowledge, this is the first study to show that central pulsatility (a measure of relative changes of BP) is an independent predictor of event-free survival. These observations may suggest that in coronary patients relative changes in BP (represented by pulsatility) are at least as important as absolute changes (represented by PP) when prognosis determination is considered. The present findings are in concordance with the previously published results suggesting aortic pulsatility correlates better with coronary atherosclerosis than central PP.5 The suggestion that BP pulsatile component is one of the most powerful predictors of the prognosis is supported by studies indicating that cyclic strain on vascular wall takes part in the development of atherosclerosis.6,12,22 Interestingly, Safar and Smulyan have recently suggested the usefulness of the calculation of the pulsatility.23 Our results do not agree with the study of Darne et al who showed steady component of BP to be more closely correlated with cardiovascular risk compared to pulsatile component.24 However, Darne et al based their analysis on peripheral pressure whereas we analyzed central ones, they studied healthy untreated population whereas our study group consisted of coronary patients majority of whom was prescribed BP-lowering drugs. As the influence of most of these agents is more pronounced on steady rather than pulsatile component of BP it is possible that this effect could influence the lack of relationship between MBP and cardiovascular risk in our study population. These differences in the studied populations and methods used account for the different results. It should be underlined that at present time coronary patients are usually prescribed 1 or even more BP-lowering drug. Therefore, results obtained from untreated coronary population probably would be useless.
Classic risk factors such as smoking or hypercholesterolemia were not related to the event-free survival in our study population. This is consistent with reports showing no significant relationship between hypercholesterolemia or hypertension and cardiovascular risk in treated coronary population.25 Patients with higher cholesterol levels have greater probability of being prescribed a lipid-lowering agent. This can probably explain the mentioned findings. This phenomenon could probably also account for the lack of the relationship between peripheral BP and cardiovascular risk in our study, as physicians treat patients according to peripheral but not central BP and the effect of cardiovascular drugs on peripheral BP can differ from its effect on central BP.15 Importantly, we found no effect of both central and peripheral MBP on the outcome. It is known that the difference in MBP between ascending aorta and peripheral artery is small. The reason for the lack of the influence of smoking on the event-free survival could be relatively small proportion of active smokers, and maybe high cessation rate during the follow-up.
A number of studies have recently suggested the usefulness of invasive BP waveform measurements.3,4,5,21 However, it would be far more convenient to measure central BP parameters noninvasively. Recently, greater attention has been given to pulse wave analysis which allows central BP assessment.9,26,27 Indeed, it was suggested that inclusion of central instead of peripheral BP values in cardiovascular risk algorithms may improve their accuracy.6,16,17 However, further studies are needed to prove this hypothesis. The present findings also suggest that studies aiming at assessment of the cardiovascular drugs influence on central BP wave will be probably continued in the near future.9,15,28,29 Although the value of central PP measurements has been studied in patients with multiple risk factors17 or renal failure,16 no previous study has examined the relationship between pulsatility and the prognosis in these or other patient groups. In addition, there is a need for studies aiming at explaining the role of BP pulsatile component in various patient subgroups, such as women, patients with heart failure, diabetes, etc.
Our study does have some limitations. Although the present study population was 3 times greater when compared with the single published study measuring central BP invasively and examining the relationship between central BP and cardiovascular risk,21 it is still possible that the results may have differed if a larger group was analyzed. We did not assess the left ventricular stroke volume. Because PP is determined directly by stroke volume, not by ejection fraction, stroke volume measurement would increase the precision of the analysis. Nevertheless, it is improbable that inclusion of stroke volume instead of EF in the multivariate analyses would significantly change our results. A fluid-filled system was used to record the ascending aortic pressure. The use of a high-fidelity pressure transducer would increase the accuracy of the recorded pressure waveform. Most study participants were prescribed cardiovascular drugs. Some of these agents have been shown to interfere with central SBP augmentation.15,29 However, the inclusion of cardiovascular drugs in the multivariate analysis did not influence the main results. Moreover, the majority of patients under consideration for coronary angiography in routine practice are taking cardiovascular drugs. It should be underlined that only patients undergoing routine nonemergency coronary angiography were included in the present study. Therefore, our results should not be applied to other patients, especially to those without CAD. On the other hand our results agree with the findings of Safar et al16 and Roman et al.17 Nevertheless, other studies are needed to explain the above doubt.
Perspectives
We showed in a large population undergoing coronary angiography that the pulsatile component of BP, measured in the ascending aorta, is one of the most important factors related to event-free survival and that it is more closely associated with cardiovascular risk than steady component. Pulsatility (a measure of relative changes of blood pressure) in the ascending aorta was also proved to be a major predictor of the cardiovascular risk. These results support prospective examination of the use of central pulsatility (especially estimated using pulse wave analysis) in future trials. Our findings may have a deep influence on the understanding of the nature of relationship between pressure wave and atherosclerosis complications development. Indeed, our results provide a rationale for a concept that rather antipulsatile than antihypertensive therapy might be of special effectiveness in coronary patients. This hypothesis should be tested in the near future. Upcoming studies will probably explain the effect of various classes of antihypertensive drugs on ascending aortic pulsatility.
| Acknowledgments |
|---|
This work was supported by Jagiellonian University, Medical College (501/ZKL/27/L).
Disclosures
None.
| Footnotes |
|---|
Received September 23, 2007; first decision October 22, 2007; accepted January 14, 2008.
| References |
|---|
|
|
|---|
2. European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21: 1011–1053.[CrossRef][Medline] [Order article via Infotrieve]
3. Nakayama Y, Tsumura K, Yamashita N, Yoshimaru K, Hayashi T. Pulsatility of ascending aortic pressure waveform is a powerful predictor of restenosis after percutaneous transluminal coronary angioplasty. Circulation. 2000; 101: 470–472.
4. Lu TM, Hsu NW, Chen YH, Lee WS, Wu CC, Ding YA, Chang MS, Lin SJ. Pulsatility of ascending aorta and restenosis after coronary angioplasty in patients > 60 years of age with stable angina pectoris. Am J Cardiol. 2001; 88: 964–968.[CrossRef][Medline] [Order article via Infotrieve]
5. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Styczkiewicz M, Po
nik-Urba
ska A, Bryniarski L, Dudek D. Ascending aortic, but not brachial blood pressure-derived indices are related to coronary atherosclerosis. Atherosclerosis. 2004; 176: 151–155.[CrossRef][Medline]
[Order article via Infotrieve]
6. Jankowski P, Bilo G, Kawecka-Jaszcz K. The pulsatile component of blood pressure – its role in the pathogenesis of atherosclerosis. Blood Press. 2007; 16: 238–245.[Medline] [Order article via Infotrieve]
7. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003; 107: 2864–2869.
8. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27: 2588–2605.
9. Agabiti-Rosei E, Mancia G, ORourke MF, Roman MJ, Safar ME, Smulyan H, Wang JG, Wilkinson IB, Williams B, Vlachopoulos C. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007; 50: 154–160.
10. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975; 51 (Suppl 4): 5–40.[Medline] [Order article via Infotrieve]
11. Dart AM, Kingwell BA. Pulse pressure – a review of mechanisms and clinical relevance. J Am Coll Cardiol. 2001; 37: 975–984.
12. Kiefer CR, McKenney JB, Trainor JF, Snyder LM. Pulse pressure-driven neutral lipid accumulation and correlative proinflammatory markers of accelerated atherogenesis. Atherosclerosis. 2005; 183: 17–24.[Medline] [Order article via Infotrieve]
13. Glynn RJ, Chae CU, Guralnik JM, Taylor JO, Hennekens CH. Pulse pressure and mortality in older people. Arch Intern Med. 2000; 160: 2765–2772.
14. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001; 103: 1245–1249.
15. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, ORourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113: 1213–1225.
16. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarch PM, London GM. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002; 39: 735–738.
17. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure. The Strong Heart Study. Hypertension. 2007; 50: 197–203.
18. Dart AM, Gatzka CD, Kingwell BA, Willson K, Cameron JD, Liang YL, Berry KL, Wing LM, Reid CM, Ryan P, Beilin LJ, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Morgan TO, West MJ. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension. 2006; 47: 785–790.
19. ORourke MF, Nichols WW, Safar ME. Brachial and central arterial pressure. Hypertension. 2006; 48: e1.
20. Staessen JA, Thijs L, OBrien ET, Bulpitt CJ, de Leeuw PW, Fagard RH, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, Safar ME. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens. 2002; 15: 835–843.[CrossRef][Medline] [Order article via Infotrieve]
21. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Perez G, Mendez AJ. Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol. 2005; 96: 645–648.[CrossRef][Medline] [Order article via Infotrieve]
22. Sakamoto H, Aikawa M, Hill CC, Weiss D, Taylor WR, Libby P, Lee RT. Biomechanical strain induces class A scavenger receptor expression in human monocyte/macrophages and THP-1 cells. A potential mechanism of increased atherosclerosis in hypertension. Circulation. 2001; 104: 109–114.
23. Safar ME, Smulyan H. The blood pressure measurement-revisited. Am Heart J. 2006; 152: 417–419.[CrossRef][Medline] [Order article via Infotrieve]
24. Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension. 1989; 13: 392–400.
25. De Bacquer D, De Backer G, Ostör E, Simon J, Pyörälä K. Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil. 2003; 10: 289–295.[CrossRef][Medline] [Order article via Infotrieve]
26. London GM, Asmar RG, ORourke MF, Safar MF. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004; 43: 92–99.
27. Verbeke F, Segers P, Heireman S, Vanholder R, Verdonck P, Van Bortel LM. Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure amplification. Hypertension. 2005; 46: 244–248.
28. ORourke MF, Seward JB. Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. Mayo Clin Proc. 2006; 81: 1057–1068.
29. Safar ME. Mechanism(s) of systolic blood pressure reduction and drug therapy in hypertension. Hypertension. 2007; 50: 167–171.
Related Article:
Hypertension 2008 51: 819-820.
This article has been cited by other articles:
![]() |
J. Hashimoto and S. Ito Some mechanical aspects of arterial aging: physiological overview based on pulse wave analysis Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 367 - 378. [Abstract] [PDF] |
||||
![]() |
M. Cecelja, B. Jiang, K. McNeill, B. Kato, J. Ritter, T. Spector, and P. Chowienczyk Increased wave reflection rather than central arterial stiffness is the main determinant of raised pulse pressure in women and relates to mismatch in arterial dimensions: a twin study. J. Am. Coll. Cardiol., August 18, 2009; 54(8): 695 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Williams, P. S. Lacy, and for the CAFE and the ASCOT (Anglo-Scandinavian Car Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) Study: CAFE-Heart Rate. J. Am. Coll. Cardiol., August 18, 2009; 54(8): 705 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Avolio, L. M. Van Bortel, P. Boutouyrie, J. R. Cockcroft, C. M. McEniery, A. D. Protogerou, M. J. Roman, M. E. Safar, P. Segers, and H. Smulyan Role of Pulse Pressure Amplification in Arterial Hypertension: Experts' Opinion and Review of the Data Hypertension, August 1, 2009; 54(2): 375 - 383. [Full Text] [PDF] |
||||
![]() |
M. E. Safar, A. D. Protogerou, and J. Blacher Statins, Central Blood Pressure, and Blood Pressure Amplification Circulation, January 6, 2009; 119(1): 9 - 12. [Full Text] [PDF] |
||||
![]() |
M. A. Allison, J. E. Manson, R. D. Langer, A. Aragaki, S. Smoller, C. E. Lewis, A. Thomas, W. Lawson, B. B. Cochrane, J. Hsia, et al. Association Between Different Measures of Blood Pressure and Coronary Artery Calcium in Postmenopausal Women Hypertension, November 1, 2008; 52(5): 833 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kopec and P. Podolec Central Pulse Pressure: Is It Really an Independent Predictor of Cardiovascular Risk? Hypertension, July 1, 2008; 52(1): e4 - e4. [Full Text] [PDF] |
||||
![]() |
M. E. Safar and H. Smulyan Central Blood Pressure and Hypertension Hypertension, April 1, 2008; 51(4): 819 - 820. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |